Payment 'Sunshine' Requirements Would Expand For Industry Under Senate-Passed Opioid Bill
Executive Summary
A provision to expand Sunshine Act industry reporting requirements for companies in the Senate-passed “Opioid Crisis Response Act” has caught criticism from the device sector, despite overall industry support for the legislation.
You may also be interested in...
President Signs Opioids Bill Calling For Alternative Tech, More Pain-Control Research
Industry groups praised newly enacted opioid-control legislation Oct. 24. The legislation will put more attention on existing medtech alternatives to addictive opioids and support research on new devices. Industry was positive about the new law, despite its expansion of sunshine reporting requirements that they oppose.
Sunshine Provision Retained In Opioids Bill Compromise
Congressional negotiators knitting together US Senate and House versions of opioids legislation retained “sunshine” provision opposed by industry that would expand the types of health-care professionals for whom device and drug manufacturers must report to the federal Open Payments database.
Sunshine Provision Retained In Opioids Bill Compromise
Congressional negotiators knitting together US Senate and House versions of opioids legislation retained a “sunshine” provision opposed by industry that would expand the types of health-care professionals for whom device and drug manufacturers must report to the federal Open Payments database.